• Amicus Therapeutics expands gene therapy alliance with Penn pharmaceutical-technology
    May 31, 2019
    Amicus Therapeutics has expanded its research and development (R&D) alliance with the Perelman School of Medicine at the University of Pennsylvania (Penn).
  • Penn presents positive results for targeted leukaemia drug pharmpacpeutical-technology
    April 03, 2019
    Researchers from the University of Pennsylvania (Penn) Abramson Cancer Center have announced findings from the ADMIRAL trial of gilteritinib in patients with relapsed or refractory acute myeloid leukaemia (AML) with a mutation in the Fms-like tyrosine kin
PharmaSources Customer Service